160 related articles for article (PubMed ID: 9367082)
21. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
22. [Thyroid carcinoma: genetics, diagnosis, clinical features, and surgical treatment].
Takami H; Ikeda Y; Tajima G; Kan S; Kameyama K
Nihon Geka Gakkai Zasshi; 2002 Jun; 103(6):492-4. PubMed ID: 12094702
[TBL] [Abstract][Full Text] [Related]
23. Medullary thyroid carcinoma.
Hoff AO; Hoff PM
Hematol Oncol Clin North Am; 2007 Jun; 21(3):475-88; viii. PubMed ID: 17548035
[TBL] [Abstract][Full Text] [Related]
24. Thyroid disorders. Part III: neoplastic thyroid disease.
Little JW
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Sep; 102(3):275-80. PubMed ID: 16920533
[TBL] [Abstract][Full Text] [Related]
25. [Thyroid carcinoma].
Namba H; Izumi M
Gan To Kagaku Ryoho; 1991 Jan; 18(1):22-9. PubMed ID: 1987898
[TBL] [Abstract][Full Text] [Related]
26. [Thyroid carcinoma. Diagnosis--nonoperative therapy--after care].
Möller L; Saller B; Quadbeck B; Mann K
MMW Fortschr Med; 2001 Jan; 143(1-2):26-31. PubMed ID: 11216009
[TBL] [Abstract][Full Text] [Related]
27. Drug therapy alternatives in the treatment of thyroid cancer.
O'Doherty MJ; Coakley AJ
Drugs; 1998 Jun; 55(6):801-12. PubMed ID: 9617595
[TBL] [Abstract][Full Text] [Related]
28. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
29. Oncogenes and thyroid cancer.
Vecchio G; Santoro M
Clin Chem Lab Med; 2000 Feb; 38(2):113-6. PubMed ID: 10834397
[TBL] [Abstract][Full Text] [Related]
30. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
Tallini G; Santoro M; Helie M; Carlomagno F; Salvatore G; Chiappetta G; Carcangiu ML; Fusco A
Clin Cancer Res; 1998 Feb; 4(2):287-94. PubMed ID: 9516913
[TBL] [Abstract][Full Text] [Related]
31. Advances and controversies in the management of medullary thyroid carcinoma.
Maia AL; Wajner SM; Vargas CV
Curr Opin Oncol; 2017 Jan; 29(1):25-32. PubMed ID: 27792051
[TBL] [Abstract][Full Text] [Related]
32. Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells.
Pierotti MA; Bongarzone I; Borello MG; Greco A; Pilotti S; Sozzi G
Genes Chromosomes Cancer; 1996 May; 16(1):1-14. PubMed ID: 9162191
[TBL] [Abstract][Full Text] [Related]
33. Medullary carcinoma of the thyroid.
Randolph GW; Maniar D
Cancer Control; 2000; 7(3):253-61. PubMed ID: 10832112
[TBL] [Abstract][Full Text] [Related]
34. Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes.
Penna GC; Vaisman F; Vaisman M; Sobrinho-Simões M; Soares P
Cytogenet Genome Res; 2016; 150(3-4):194-207. PubMed ID: 28231576
[TBL] [Abstract][Full Text] [Related]
35. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic markers and prognostic factors in thyroid cancer.
Vriens MR; Schreinemakers JM; Suh I; Guerrero MA; Clark OH
Future Oncol; 2009 Oct; 5(8):1283-93. PubMed ID: 19852742
[TBL] [Abstract][Full Text] [Related]
37. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.
Cerrato A; De Falco V; Santoro M
J Mol Endocrinol; 2009 Oct; 43(4):143-55. PubMed ID: 19383830
[TBL] [Abstract][Full Text] [Related]
38. Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma.
Marsh DJ; Theodosopoulos G; Martin-Schulte K; Richardson AL; Philips J; Röher HD; Delbridge L; Robinson BG
J Clin Endocrinol Metab; 2003 Apr; 88(4):1866-72. PubMed ID: 12679485
[TBL] [Abstract][Full Text] [Related]
39. Usefulness of ancillary methods for diagnosis, prognosis and targeted therapy in thyroid pathology.
Bozec A; Ilie M; Lassalle S; Hofman V; Benaim G; Long E; Santini J; Hofman P
Curr Med Chem; 2013; 20(5):639-54. PubMed ID: 23298138
[TBL] [Abstract][Full Text] [Related]
40. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma.
Bhattacharyya N
Otolaryngol Head Neck Surg; 2003 Jan; 128(1):115-23. PubMed ID: 12574769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
